26218 Federal Register / Vol. 87, No. 85 / Tuesday, May 3, 2022 / Notices 

Dated: April 27, 2022. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–09393 Filed 5–2–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Integrative, 

Functional and Cognitive Neuroscience 

Integrated Review Group; Behavioral 

Neuroendocrinology, Neuroimmunology, 

Rhythms, and Sleep Study Section. 

Date: June 1–2, 2022. 

Time: 8:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Michael Selmanoff, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5164, 

MSC 7844, Bethesda, MD 20892, 301–435– 

1119, selmanom@csr.nih.gov. 

Name of Committee: Emerging 

Technologies and Training Neurosciences 

Integrated Review Group; Bioengineering of 

Neuroscience, Vision and Low Vision 

Technologies Study Section. 

Date: June 1–2, 2022. 

Time: 9:30 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Robert C. Elliott, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5190, 

MSC 7846, Bethesda, MD 20892, 301–435– 

3009, elliotro@csr.nih.gov. 

Name of Committee: Biological Chemistry 

and Macromolecular Biophysics Integrated 

Review Group; Synthetic and Biological 

Chemistry A Study Section. 

Date: June 1–2, 2022. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Anita Szajek, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4187, 

Bethesda, MD 20892, 301–827–6276, 

anita.szajek@nih.gov. 

Name of Committee: Cardiovascular and 

Respiratory Sciences Integrated Review 

Group; Lung Cellular, Molecular, and 

Immunobiology Study Section. 

Date: June 1–2, 2022. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: George M. Barnas, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 2180, 

MSC 7818, Bethesda, MD 20892, 301–435– 

0696, barnasg@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: April 27, 2022. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–09394 Filed 5–2–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: LZK-Targeting Cancer 

Therapeutic 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Cancer Institute 

(NCI), an institute of the National 

Institutes of Health (NIH), Department 

of Health and Human Services (HHS), is 

contemplating the grant of an Exclusive 

Patent License to practice the inventions 

embodied in the Patents and Patent 

Applications listed in the 

Supplementary Information section of 

this Notice to Uereka Biosciences Inc. 

(‘‘Uereka’’), headquartered in East 

Wakefield, NH. 

DATES: Only written comments and/or 

applications for a license which are 

received by the National Cancer 

Institute’s Technology Transfer Center 

on or before May 18, 2022 will be 

considered. 

ADDRESSES: Requests for copies of the 

patent applications, inquiries, and 

comments relating to the contemplated 

Exclusive Patent License should be 

directed to: Jasmine Yang, Ph.D., Senior 

Technology Transfer Manager, NCI 

Technology Transfer Center, Telephone: 

301–624–8746; Email: jasmine.yang@

nih.gov. 

SUPPLEMENTARY INFORMATION: 

Intellectual Property 

(1) HHS Ref. No.: E–163–2020–0, 

Entitled: Leucine Zipper-bearing 

Kinase (LZK) Targeting Degraders 

and Methods of Use 

(a) US Provisional Patent Application 

No.: 63/073,835 HHS Ref. No.: E– 

163–2020–0–US–01 Filing Date: 

September 2, 2020 

(b) PCT Patent Application No.: PCT/ 

US2021/048600 HHS Ref. No.: E– 

163–2020–0–PCT–02 Filing Date: 

September 1, 2021 

(2) HHS Ref. No.: E–169–2021–0, 

Entitled: LZK-Targeting ATPCompetitive Catalytic Inhibitors 

Suppress LZK Catalytic Activity, 

Inhibit MYC Expression, Inhibit 

AKT Activation, and Promote 

Cancer Cell Death and Tumor 

Regression 

(a) US Provisional Patent Application 

No.: 63/239,797 HHS Ref. No.: E– 

169–2021–0–US–01 Filing Date: 

September 1, 2021 

The patent rights in these inventions 

have been assigned and/or exclusively 

licensed to the government of the 

United States of America. 

The prospective exclusive license 

territory may be worldwide, and the 

field of use may be limited to the 

following: 

‘‘LZK-targeting small molecules 

inhibitors or PROTACs to treat cancers 

overexpressing LZK..’’ 

Leucine-Zipper Kinase (LZK, encoded 

by MAP3K13, a resident gene of the 3q 

amplicon) is highly expressed in the 

mouse brain, particularly the 

cerebellum, but also in the intestine, 

olfactory bulb, liver, and kidney and 

shown to promote neurite growth. In 

addition, LZK overexpression and 3q 

amplification is associated with cancer 

such as squamous cell carcinomas 

(SCC). The Intellectual Property are 

directed to compositions of matter to 

LZK kinase inhibitors as well as the 

combination of a LZK binding moiety to 

an E3-ligase binding moiety via a linker 

and specific structures to each 

component as well as methods of using 

said compositions to treat LZK 


lotter on DSK11XQN23PROD with NOTICES1